TACR2 and obesity due to melanocortin 4 receptor deficiency: Drug treatments that target NeuroKinin 2 Receptor (NK2R) could be a viable option for fighting obesity by reducing hunger, burning energy, and improving insulin resistance, without causing unwanted side effects [45].